CN101616668B - 药用组合物 - Google Patents
药用组合物 Download PDFInfo
- Publication number
- CN101616668B CN101616668B CN2008800016680A CN200880001668A CN101616668B CN 101616668 B CN101616668 B CN 101616668B CN 2008800016680 A CN2008800016680 A CN 2008800016680A CN 200880001668 A CN200880001668 A CN 200880001668A CN 101616668 B CN101616668 B CN 101616668B
- Authority
- CN
- China
- Prior art keywords
- preparation
- medicine
- sodium
- cellulose
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008800016680A CN101616668B (zh) | 2007-01-05 | 2008-01-07 | 药用组合物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710036237.5 | 2007-01-05 | ||
CNA2007100362375A CN101214242A (zh) | 2007-01-05 | 2007-01-05 | 新的药用组合物 |
CN2008800016680A CN101616668B (zh) | 2007-01-05 | 2008-01-07 | 药用组合物 |
PCT/CN2008/000048 WO2008086733A1 (fr) | 2007-01-05 | 2008-01-07 | Nouvelle composition pharmaceutique |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101616668A CN101616668A (zh) | 2009-12-30 |
CN101616668B true CN101616668B (zh) | 2013-01-09 |
Family
ID=39620792
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007100362375A Pending CN101214242A (zh) | 2007-01-05 | 2007-01-05 | 新的药用组合物 |
CN2008800016680A Active CN101616668B (zh) | 2007-01-05 | 2008-01-07 | 药用组合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007100362375A Pending CN101214242A (zh) | 2007-01-05 | 2007-01-05 | 新的药用组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8138214B2 (zh) |
EP (1) | EP2116242B1 (zh) |
JP (1) | JP5295123B2 (zh) |
CN (2) | CN101214242A (zh) |
WO (1) | WO2008086733A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105232489A (zh) * | 2014-07-01 | 2016-01-13 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101024643A (zh) | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
CN101317842A (zh) | 2007-06-07 | 2008-12-10 | 上海艾力斯医药科技有限公司 | 一种咪唑-5-羧酸衍生物的治疗用途 |
US9138309B2 (en) | 2010-02-05 | 2015-09-22 | Allergan, Inc. | Porous materials, methods of making and uses |
US9205577B2 (en) * | 2010-02-05 | 2015-12-08 | Allergan, Inc. | Porogen compositions, methods of making and uses |
US11202853B2 (en) * | 2010-05-11 | 2021-12-21 | Allergan, Inc. | Porogen compositions, methods of making and uses |
CN103263395A (zh) * | 2013-06-10 | 2013-08-28 | 南京正宽医药科技有限公司 | 一种替米沙坦片剂及其制备方法 |
CN111018841B (zh) | 2013-11-01 | 2023-04-07 | 深圳信立泰药业股份有限公司 | 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物 |
CN105078974A (zh) * | 2014-05-23 | 2015-11-25 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯固体分散体及药物组合物 |
CN106539690B (zh) * | 2015-09-18 | 2020-08-04 | 天士力医药集团股份有限公司 | 一种液体冷却滴丸的连续智能制备方法 |
US20180168932A1 (en) * | 2016-12-20 | 2018-06-21 | Apotex Technologies Inc. | Meloxicam Dosage Forms |
CN112245396B (zh) * | 2020-09-28 | 2022-11-15 | 北京华氏开元医药科技有限公司 | 四氢异喹啉类衍生物药物制剂及其制备方法 |
US11655240B1 (en) | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
CN117159556A (zh) * | 2022-05-27 | 2023-12-05 | 北京远大九和药业有限公司 | 一种药物组合物及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1071426A (zh) * | 1991-10-04 | 1993-04-28 | 化学药物研究股份公司 | 咪唑-5-羧酸衍生物的新的缩醛的制备方法 |
CN1832742A (zh) * | 2003-07-31 | 2006-09-13 | 尼科克斯公司 | 用于治疗心血管疾病的血管紧张素ii受体阻断剂氯沙坦、缬沙坦、坎地沙坦、替米沙坦、依普罗沙坦和奥美沙坦的硝基氧基衍生物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
JPH083162A (ja) * | 1994-04-19 | 1996-01-09 | Tanabe Seiyaku Co Ltd | イミダゾピリジン誘導体及びその製法 |
US5990134A (en) * | 1998-08-12 | 1999-11-23 | Taylor Pharmaceuticals | Oral droperidol compositions and method for treating migraine |
CN101024643A (zh) * | 2006-02-20 | 2007-08-29 | 上海艾力斯医药科技有限公司 | 咪唑-5-羧酸类衍生物、制备方法及其应用 |
EP2103610B1 (en) * | 2006-12-06 | 2011-09-21 | Shanghai Allist Pharmaceutical., Inc. | Salts of imidazol-5-carboxylic acid derivatives, preparation methods and use thereof |
-
2007
- 2007-01-05 CN CNA2007100362375A patent/CN101214242A/zh active Pending
-
2008
- 2008-01-07 JP JP2009544355A patent/JP5295123B2/ja active Active
- 2008-01-07 EP EP08700608.6A patent/EP2116242B1/en active Active
- 2008-01-07 WO PCT/CN2008/000048 patent/WO2008086733A1/zh active Application Filing
- 2008-01-07 CN CN2008800016680A patent/CN101616668B/zh active Active
-
2009
- 2009-07-02 US US12/497,282 patent/US8138214B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1071426A (zh) * | 1991-10-04 | 1993-04-28 | 化学药物研究股份公司 | 咪唑-5-羧酸衍生物的新的缩醛的制备方法 |
CN1832742A (zh) * | 2003-07-31 | 2006-09-13 | 尼科克斯公司 | 用于治疗心血管疾病的血管紧张素ii受体阻断剂氯沙坦、缬沙坦、坎地沙坦、替米沙坦、依普罗沙坦和奥美沙坦的硝基氧基衍生物 |
Non-Patent Citations (3)
Title |
---|
Elizabeth M. Naylor et al.Potent imidazole angiotensin II antagonists:acyl sulfonamides and acyl sulfamides as tetrazole replacements.《Bioorganic & Medicinal Chemistry Letters》.1994,第4卷(第1期),69-74. |
Elizabeth M. Naylor et al.Potent imidazole angiotensin II antagonists:acyl sulfonamides and acyl sulfamides as tetrazole replacements.《Bioorganic & * |
Medicinal Chemistry Letters》.1994,第4卷(第1期),69-74. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105232489A (zh) * | 2014-07-01 | 2016-01-13 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 |
CN105232489B (zh) * | 2014-07-01 | 2019-06-11 | 深圳信立泰药业股份有限公司 | 一种阿利沙坦酯固体分散体及含有该固体分散体的药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
JP5295123B2 (ja) | 2013-09-18 |
CN101214242A (zh) | 2008-07-09 |
EP2116242A4 (en) | 2013-02-13 |
WO2008086733A1 (fr) | 2008-07-24 |
US8138214B2 (en) | 2012-03-20 |
CN101616668A (zh) | 2009-12-30 |
US20090326025A1 (en) | 2009-12-31 |
EP2116242B1 (en) | 2016-10-12 |
EP2116242A1 (en) | 2009-11-11 |
JP2010514813A (ja) | 2010-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101616668B (zh) | 药用组合物 | |
CN101278932B (zh) | 含有扎托布洛芬的缓释药物组合物及其制备方法与应用 | |
CN101203211B (zh) | 药物组合物 | |
CN101212958A (zh) | 基于两种聚合物的控释药物组合物及其制备方法 | |
US20130123294A1 (en) | Formulations containing nalbuphine and uses thereof | |
WO2010078429A1 (en) | Pharmaceutical dosage forms and methods of manufacturing same | |
WO2006087919A1 (ja) | 難水溶性物質含有微細化組成物 | |
CN104650091A (zh) | 替格瑞洛的微粉化及其晶型,以及制备方法和药物应用 | |
JP5775085B2 (ja) | c−METキナーゼ阻害剤の製剤 | |
AU2016372683A1 (en) | Complexes of celecoxib and its salts and derivatives process for the preparation thereof and pharmaceutical compositions containing them | |
CN102512393A (zh) | 一种托伐普坦的口腔崩解片 | |
CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
CN105078974A (zh) | 一种阿利沙坦酯固体分散体及药物组合物 | |
CN101370484B (zh) | 含有厄贝沙坦的固体药物组合物 | |
CN110035751A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
WO2012159511A1 (zh) | 阿齐沙坦固体分散体及其制备方法和药物组合物 | |
CN102088972B (zh) | 含有咪唑-5-羧酸类衍生物的药用组合物,其制备方法及用途 | |
CN1732953B (zh) | 一种治疗高血压的分散片 | |
JP2001522872A (ja) | 薬物高充填性の即時放出性または放出を修飾した経口用投与処方およびその製法 | |
CN101152155A (zh) | 盐酸伊伐布雷定固体药物组合物及其制备方法 | |
CN110035756A (zh) | 含有他达拉非的药物配制品 | |
CN102349903B (zh) | 一种含有左旋氨氯地平和缬沙坦的药物组合物及其制备方法 | |
CN102885810B (zh) | 一种坎地沙坦酯双释胶囊及其制备方法 | |
CN103007286A (zh) | 一种托伐普坦的固体药物组合物 | |
CN114306263B (zh) | 一种复方降压药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN SALUBRIS ASSETS MANAGEMENT CO., LTD. Free format text: FORMER OWNER: SHANGHAI ALLIST PHARMACEUTICALS CO., LTD. Effective date: 20130106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200000 PUDONG NEW ZONE, SHANGHAI CITY TO: 518040 SHENZHEN, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130106 Address after: 518040, Anhui building, south of Shennan Road, Shenzhen, Guangdong, 1921, Futian District Patentee after: Shenzhen Xinlitai Asset Management Co.,Ltd. Address before: 200000 Shanghai Zhangjiang hi tech Park Cailun Road No. 4 Building 780 Patentee before: SHANGHAI ALLIST PHARMACEUTICALS, Inc. |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20091230 Assignee: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Assignor: Shenzhen Xinlitai Asset Management Co.,Ltd. Contract record no.: 2013440020018 Denomination of invention: Compound cortex steroid medicinal composition Granted publication date: 20130109 License type: Common License Record date: 20130123 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: SHENZHEN SALUBRIS ASSETS MANAGEMENT CO., LTD. Effective date: 20150710 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150710 Address after: Shenzhen City, Guangdong Province, 518040 Shennan Road No. 6009 Che Kung Temple Green Plaza building 37 layer Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Address before: 518040, Anhui building, south of Shennan Road, Shenzhen, Guangdong, 1921, Futian District Patentee before: Shenzhen Xinlitai Asset Management Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017 Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. Address before: 518040 37 / F, main building, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Shenzhen, Guangdong Patentee before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd. |
|
CP02 | Change in the address of a patent holder |